A Phase 2 interventional study of LP352, bexicaserin in Developmental and Epileptic Encephalopathy, Dravet Syndrome and Lennox-Gastaut Syndrome, sponsored by Longboard Pharmaceuticals. Completed at 28 sites in 2 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Longboard Pharmaceuticals (part of H. Lundbeck A/S) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.
Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 21st largest by enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2022, is one of 9 in phase 2, and was the 49th registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:
Scripps Translational Science Institute · Sites in United States
Ages 2–60
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 2–12
The University of Texas Health Science Center, Houston · Sites in United States
Ages 16+
University of Colorado, Denver · Sites in United States
Ages 12 mo–24 mo
Encoded Therapeutics · Sites in United States, Australia, United Kingdom
Ages 6 mo–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 20 · Phase 4 3
First in 2000; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is above the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 36 across the 43 interventional studies, 58 across the 11 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Longboard Pharmaceuticals, one of the names counted as H. Lundbeck A/S. Under that name alone:
Longboard Pharmaceuticals is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
H. Lundbeck A/S has 7 studies filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Myoclonic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06872125Phase 3Stoke Therapeutics, IncA Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | 2027-03 |
| NCT04462770Phase 3EpygenixA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | 2027-04 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 61 studies in Epilepsies, Myoclonic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
This Phase 2, multicenter, open-label, multiple-dose extension clinical study is designed to evaluate long-term safety of LP352 in subjects with developmental and epileptic encephalopathy who completed Study LP352-201.
The study consists of a Screening Period (Day -1) and a 50-week open-label Treatment Period that includes a 15-day Up-titration Period (during which time subjects will titrate up to their highest tolerated doses) and an open-label Maintenance Period (48 weeks). The Treatment Period will be followed by a Down-titration/Taper Period (up to 15 days) and Follow-up Period (14 days after completion of down-titration). The starting dose of up-titration will be 6 mg TID. The target final maintenance doses are 6 mg TID, 9 mg TID, and 12 mg TID after a 15-day up-titration period, if tolerated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will be titrated up to highest tolerated dose of LP352 during a 15-day period, followed by a 48-week maintenance period and a 15-day taper/down titration period.
Drug: LP352, bexicaserin
LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
Treatment-emergent Adverse Events
Incidence and severity of treatment-emergent adverse events, including serious adverse events and adverse events leading to study discontinuation and clinically significant changes in vital signs, physical examination endpoints, clinical safety laboratory values and ECGs
Time frame: Baseline up to Week 52
Columbia-Suicide Severity Rating Scale (C-SSRS) Response
Type of Suicidal Ideation, Intensity (1 - 5, with 5 being most severe), Suicidal Behavior
Time frame: Baseline up to Week 52
Patient Health Questionnaire-9 Total Score and Question 9 Score
Severity Rating Scale: 0 - 27; higher scores indicate greater severity of depressive disorder
Time frame: Baseline up to Week 52
Percent Change from Baseline in Observed Countable Motor Seizure Frequency During the Treatment Period
Baseline Used for Seizure Frequency = Baseline from Study LP352-201 and Baseline from Study LP352-202
Time frame: Baseline to Week 50
Proportion of Subjects with > 50% Reduction in Total Seizures During the Treatment Period
Time frame: Baseline to Week 50
Percent Reduction in Individual Seizure Type During the Treatment Period
Time frame: Baseline to Week 50
Proportion of Subjects Requiring Rescue Medication During the Treatment Period
Time frame: Baseline to Week 50
Percent Change from Baseline in the Number of Episodes of Status Epilepticus During the Treatment Period
Time frame: Baseline to Week 50
Percent of Subjects with Countable Motor Seizure-free Days During the Treatment Period
Time frame: Baseline to Week 50
Percentage Change from Baseline in Non-motor and Difficult to Count Seizures
Time frame: Baseline to Week 50
LGS: Percentage Change from Baseline in the Frequency of Observed Drop Seizures Over the Treatment Period
Time frame: Baseline to Week 50
Ran from Nov 2022 to primary completion in Dec 2024, 25 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bexicaserin